Evidence map›Paper›PMID 37383088›Full record

ArticleJournal of liver cancer2021

A case report of a patient presented with skin ulcer after treatment of lenvatinib.

Serin Cha, Dong Woo Kim, Jung Wan Choe, Tae Hyung Kim, Seung Young Kim, Jong Jin Hyun, Sung Woo Jung, Ja Seol Koo, Young Kul Jung, Hyung Joon Yim

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Journal of liver cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Serin ChaDepartment of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea.ORCID https://orcid.org/0000-0002-3863-4768
Dong Woo KimDepartment of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea.ORCID https://orcid.org/0000-0001-6767-426X Jung Wan Choe: https://orcid.org/0000-0003-0634-5141
Jung Wan ChoeDepartment of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea.
Tae Hyung KimDepartment of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea.ORCID https://orcid.org/0000-0002-7747-4293
Seung Young KimDepartment of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea.ORCID https://orcid.org/0000-0001-8933-7715
Jong Jin HyunDepartment of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea.ORCID https://orcid.org/0000-0002-5632-7091
Sung Woo JungDepartment of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea.ORCID https://orcid.org/0000-0003-1954-1678
Ja Seol KooDepartment of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea.ORCID https://orcid.org/0000-0002-1202-075X
Young Kul JungDepartment of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea.ORCID https://orcid.org/0000-0002-6566-1382
Hyung Joon YimDepartment of Internal Medicine, Korea University Ansan Hospital, Ansan, Korea.ORCID https://orcid.org/0000-0002-6036-2754
Korea University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 60-year-old man diagnosed with unresectable hepatocellular carcinoma (HCC) presented to the hospital with pain in the perineal region. He had been taking lenvatinib every day for 2 months after he was diagnosed with HCC with metastases to the lymph node, small bowel mesentery, and retroperitoneal space. Enhanced abdominal computed tomography revealed mild elevation in intensity in the perineal subcutaneous tissue with subcutaneous emphysema. The patient was diagnosed with Common Terminology Criteria for Adverse Events grade 3, skin ulceration of stage IV with full-thickness skin loss and tissue necrosis in the muscular layer. The patient was taken off the medication with prescription of antibiotics, and after 3 weeks, the skin has fully recovered. This is the first report of an HCC patient who presented with a skin ulceration of stage IV after lenvatinib treatment. We recommend stopping the medication immediately and changing to alternative treatments with appropriate supportive care.

Indexed as

Adverse drug eventHepatocellular carcinomaLenvatinib mesylateProtein kinase inhibitorSkin ulcer

Identifiers

PMID37383088
PMCPMC10035686
OpenAlexW3202259920

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.